David Gerring

The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists.

Insense Ltd. develops products for treatment of wounds and skin conditions. Its development activity is concentrated on dermatology products for both professional and consumer applications. The company was founded in 2001 by Paul James Davis and is headquartered in Bedford, the United Kingdom.

Part of Novacyt SAS, Biotec Laboratories Ltd. is a British company that produces and distributes diagnostic reagents, test kits and dehydrated culture media. The company is based in Ipswich, UK. Biotec Laboratories was acquired by Lab 21 Ltd. on March 03, 2009.

Microgen Bioproducts Ltd. develops, manufactures, distributes, and markets clinical laboratory products. It offers biochemical identification and latex agglutination kits, path-check hygiene and pregnancy tests, pulsifier, and bacterial typing antisera. The company was founded in 1994 and is headquartered in Camberley, the United Kingdom.

Lab 21 Ltd. operates as a healthcare diagnostics company. It specializes in providing patients, doctors, hospitals ,and healthcare providers with diagnostic information for disease identification, disease predisposition, and personalized medicine, to help in managing health problems. It also offers diagnostic products and services and supports blood bank screening, medical diagnostics, and drug discovery. The company was founded in April 2005 by Berwyn E. Clarke and is headquartered in Cambridge, the United Kingdom.

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom.

Closed Loop Medicine Ltd. operates as a new breed of therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised regimens. It combines proven drugs with digital therapeutics enabling the digitisation and data capture of an entire care continuum. The company was founded by Felicity Sartain, Hakim Yadi, Paul Goldsmith, and David Cox in 2017 and is headquartered in London, the United Kingdom.

Part of Sanofi, Genzyme Ltd is a company that specializes in biological healthcare products. The company is based in Cambridge, MA.

Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom.

Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012.

Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates.

Part of UDG Healthcare Ltd. (Dublin), PHMR Ltd. is a healthcare consulting British company that specializes in insight-enabled pricing and market access approaches to ensure successful product launch and life-cycle management. The company is based in London, UK. The company helps its clients in the healthcare industries build value for their products by using academically-proven analytical methods to find and form clinical, economic, and humanistic evidence. PHMR is an international team of highly qualified health economists and research scientists. The company was founded by Mark Ratcliffe, who has been the CEO since incorporation. PHMR was acquired by UDG Healthcare Ltd. (Dublin) on January 26, 2021 for $43.75 million.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom.

Part of Piper Sandler Cos., Piper Sandler Ltd. is a brokerage services provider. The company is based in London, UK. The British company was founded in 1999. Neil Robert Mackison has been the CEO of the company since 2006.

Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.